Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 05.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e the Company’s securities from listing. Item 5.02 Resignation of Director and Officer On August 31, 2025, Michael P |
| 10.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Resignation of a Director On March 4, 2025, Amy Griffith informed the Board of Directors of the Co |
| 29.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Appointment of an Officer. On October 23, 2024, Elizabeth Ng notified the Company’s Board of Direc |
| 08.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Appointment of a Director. On March 4, 2024, Amy Griffith has been appointed as a director of Ocea |
| 04.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Resignation of an Officer; Appointment of an Officer. On March 1, 2024, the appointment of Jolie |
| 15.11.2023 | Item 4.02 — Bilanzkorrekturen | EXTREM | SEC | Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed In |
Stammdaten
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.
Unternehmen & Branche
| Name | Ocean Biomedical, Inc. |
|---|---|
| Ticker | OCEA |
| CIK | 0001869974 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 237.271 USD |
| Beta | 0,41 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-03-31 | 10-Q | -8,240,000 | -0.09 | 1,582,000 | -92,399,000 | |
| 2024-12-31 | 10-K | -9,480,000 | -0.34 | 902,000 | -97,616,000 | |
| 2024-09-30 | 10-Q | -5,528,000 | -0.20 | 1,132,000 | -98,085,000 | |
| 2024-09-30 | 10-K | -3,704,000 | -0.13 | -96,261,000 | ||
| 2024-06-30 | 10-Q | -17,234,000 | -0.63 | 1,851,000 | -92,743,000 | |
| 2024-03-31 | 10-Q | 12,999,000 | 0.48 | 2,946,000 | -75,783,000 | |
| 2023-12-31 | 10-K | -114,466,000 | -4.35 | 5,501,000 | -90,763,000 | |
| 2023-09-30 | 10-Q | -14,087,000 | -0.53 | 1,031,000 | -75,224,000 | |
| 2023-06-30 | 10-Q | -11,431,000 | -0.43 | 20,921,000 | -61,657,000 | |
| 2023-03-31 | 10-Q | -72,092,000 | -2.90 | 24,978,000 | -54,753,000 | |
| 2022-12-31 | 10-K | -17,359,000 | -0.74 | 1,842,000 | -10,819,000 | |
| 2022-09-30 | 10-Q | -3,668,000 | -0.16 | 109,128,586 | -9,836,000 | |
| 2022-06-30 | 10-Q | -7,333,000 | -0.31 | 108,561,277 | -9,537,000 | |
| 2022-03-31 | 10-Q | -5,375,000 | 108,342,352 | -7,494,000 | ||
| 2021-12-31 | 10-K | -564,110 | 108,652,342 | -6,663,000 | ||
| 2021-09-30 | 10-Q | -42,545 | 108,937,246 | -1,322,619 | ||
| 2021-06-30 | 10-Q | -82 | 24,918 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.